Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

9.1K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.1K
Drugs that Stabilize Microtubules01:15

Drugs that Stabilize Microtubules

2.9K
Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.9K
Cancer Therapies02:49

Cancer Therapies

10.6K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
10.6K
Drugs that Destabilize Microtubules01:10

Drugs that Destabilize Microtubules

4.3K
Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...
4.3K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

6.2K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
6.2K
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

1.5K
1.5K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A review on recent advancements of iridium (III) complexes as antiproliferative and photodynamic therapy agents.

European journal of medicinal chemistry·2026
Same author

Inhibition of GPR68 induces ferroptosis in diffuse intrinsic pontine gliomas.

Frontiers in oncology·2026
Same author

Human neural organoid modeling of diffuse midline glioma captures the complexity of patient tumors.

Journal of neuro-oncology·2026
Same author

Psilocybin: Chemical Foundations and Emerging Therapeutic Potential.

Mini reviews in medicinal chemistry·2026
Same author

Effects of combination therapy of a CDK4/6 and MEK inhibitor in diffuse midline glioma preclinical models.

PloS one·2025
Same author

Hyperpolarized Carbon-13 Metabolic Imaging Differentiates Distinctive Molecular Phenotypes in Diffuse Midline Gliomas.

Molecules (Basel, Switzerland)·2025
Same journal

Recent Advancements in the Development of Heterocyclic Scaffolds as Potential Anti-cancer Agents Targeting EGFR and VEGFR-2.

Mini reviews in medicinal chemistry·2026
Same journal

Exploring the Anticancer Potential of Synthetic β-Carboline Derivatives: A Comprehensive Systematic Review.

Mini reviews in medicinal chemistry·2026
Same journal

KIF20A in Human Malignancies: Oncogenic Mechanisms and Therapeutic Targeting Strategies.

Mini reviews in medicinal chemistry·2026
Same journal

Phytocompound-loaded Biomaterial-based Scaffolds: Emerging Strategies for Wound Healing Applications.

Mini reviews in medicinal chemistry·2026
Same journal

Bioprospecting of Natural Products as Sources of New Multitarget Therapies.

Mini reviews in medicinal chemistry·2026
Same journal

Boosting the Functional Potential of Pectin: Recent Progress in Antimicrobial Applications through Structural Modifications (2020-2025).

Mini reviews in medicinal chemistry·2026
See all related articles

Related Experiment Video

Updated: Mar 28, 2026

Facile Preparation of 4-Substituted Quinazoline Derivatives
11:51

Facile Preparation of 4-Substituted Quinazoline Derivatives

Published on: February 15, 2016

12.5K

Imidazoquinolines: Recent Developments in Anticancer Activity.

Shivaputra A Patil1, Siddappa A Patil, Renukadevi Patil

  • 1Pharmaceutical Sciences Department, College of Pharmacy, Rosalind Franklin University of Medicine and Science, 3333 Green Bay Road, North Chicago, IL 60064, USA. shivaputra.patil@rosalindfranklin.edu.

Mini Reviews in Medicinal Chemistry
|December 18, 2015
PubMed
Summary
This summary is machine-generated.

Small-molecule agonists targeting toll-like receptor 7 and 8 (TLR7/8) show significant anticancer activity. This review covers imidazoquinolines, highlighting their synthesis, SAR, and biological roles in cancer treatment.

More Related Videos

Preclinical Assessment of the Bioactivity of the Anticancer Coumarin OT48 by Spheroids, Colony Formation Assays, and Zebrafish Xenografts
09:20

Preclinical Assessment of the Bioactivity of the Anticancer Coumarin OT48 by Spheroids, Colony Formation Assays, and Zebrafish Xenografts

Published on: June 26, 2018

8.9K
Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors
10:29

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors

Published on: May 9, 2025

2.6K

Related Experiment Videos

Last Updated: Mar 28, 2026

Facile Preparation of 4-Substituted Quinazoline Derivatives
11:51

Facile Preparation of 4-Substituted Quinazoline Derivatives

Published on: February 15, 2016

12.5K
Preclinical Assessment of the Bioactivity of the Anticancer Coumarin OT48 by Spheroids, Colony Formation Assays, and Zebrafish Xenografts
09:20

Preclinical Assessment of the Bioactivity of the Anticancer Coumarin OT48 by Spheroids, Colony Formation Assays, and Zebrafish Xenografts

Published on: June 26, 2018

8.9K
Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors
10:29

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors

Published on: May 9, 2025

2.6K

Area of Science:

  • Oncology
  • Immunology
  • Medicinal Chemistry

Background:

  • Cancer remains a significant global health challenge despite advances in drug discovery.
  • Small-molecule agonists of toll-like receptor 7 and 8 (TLR7/8) are emerging as promising anticancer agents.
  • Imidazoquinolines and dual phosphoinositide 3-kinase/mammalian target of rapamycin inhibitors represent key therapeutic candidates.

Purpose of the Study:

  • To review the synthesis, structure-activity relationships (SAR), and biological activities of clinically studied imidazoquinolines.
  • To explore novel preclinical imidazoquinolines with potential anticancer applications.
  • To consolidate current knowledge on TLR7/8 agonists in cancer therapy.

Main Methods:

  • Literature review of preclinical and clinical studies on imidazoquinolines.
  • Analysis of synthesis pathways and SAR data for anticancer efficacy.
  • Evaluation of biological activities, including antitumoral effects.

Main Results:

  • Imidazoquinolines demonstrate profound antitumoral activity through TLR7/8 agonism.
  • Clinically relevant compounds like Imiquimod and Resiquimod showcase therapeutic potential.
  • Emerging preclinical imidazoquinolines offer new avenues for cancer treatment development.

Conclusions:

  • TLR7/8 agonists, particularly imidazoquinolines, are vital in advancing cancer drug discovery.
  • Understanding SAR is crucial for optimizing the design of novel anticancer agents.
  • Continued research into imidazoquinolines holds promise for improved cancer patient outcomes.